• About us
• Contact

Advertisement

Product › Details

antibody-drug conjugate (ADC)

	Next higher product group	cancer drug

Record changed: 2023-10-30

Advertisement

More documents for antibody-drug conjugate (ADC)

• [1] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
• [2] GSK plc. (10/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20089". London....
• [3] Merck & Co., Inc.. (10/19/23). "Press Release: Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs". Basking Ridge, NJ & Rahway, NJ....
• [4] MediLink Therapeutics (Suzhou) Co., Ltd.. (10/12/23). "Press Release: MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate". Suzhou....
• [5] BioNTech SE. (4/3/23). "Press Release: BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors". Mainz & Shanghai....
• [6] Merck & Co., Inc.. (12/22/22). "Press Release: Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer". Rahway, NJ....
• [7] Sotio Biotech a.s.. (11/29/22). "Press Release: Sotio Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences". Prague....
• [8] Pheon Therapeutics Ltd.. (9/28/22). "Press Release: Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors". London....
• [9] Heidelberg Pharma AG. (9/9/22). "Press Release: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate". Ladenburg....
• [10] Heidelberg Pharma AG. (7/13/22). "Press Release: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate (ad hoc)". Ladenburg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.